加载中
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
前收盘价
US$1.735
+US$0.415 · +31.44%
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
日内区间
当前US$1.735
52周区间
当前US$1.735
历史价格可能经过调整并有所延迟。
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
日内区间
当前US$1.735
52周区间
当前US$1.735
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 200万 USD | 1100万 USD | — | — | 25万 USD |
| 销货成本 | 4307.3万 USD | 92.5万 USD | 122.1万 USD | 119.9万 USD | 5827.4万 USD |
| 毛利 | −4107.3万 USD | 1007.5万 USD | −122.1万 USD | −119.9万 USD | −5802.4万 USD |
| 研究与开发 | 4357.3万 USD | 6309.5万 USD | 1.04亿 USD | 7934.7万 USD | 5827.4万 USD |
| 销售、一般及管理费用 | 1763.2万 USD | 2184.8万 USD | 2595.6万 USD | 2879.3万 USD | 3841.6万 USD |
| 营业费用 | 1823.2万 USD | 8401.8万 USD | 1.28亿 USD | 1.07亿 USD | 3841.6万 USD |
| 利息收入 | 84.3万 USD | 336.9万 USD | 631.2万 USD | 164.8万 USD | 35万 USD |
| 利息支出 | — | — | — | — | 3000 USD |
| 折旧和摊销 | 37.3万 USD | 92.5万 USD | 122.1万 USD | 119.9万 USD | 133万 USD |
| 营业利润 | −5930.5万 USD | −7394.3万 USD | −1.3亿 USD | −1.08亿 USD | −9644万 USD |
| 净利润 | −5960.7万 USD | −6977.6万 USD | −1.23亿 USD | −1.05亿 USD | −9540.2万 USD |
公司数据更新于 2026年11月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$250
上涨空间 14309.22%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年4月6日 | 1:50 | — | — |
已生效 2026年4月6日
1:50
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
